Navigation Links
TissuGlu® Surgical Adhesive Named 2012 Medical Design Excellence Awards Finalist
Date:4/2/2012

PITTSBURGH, April 2, 2012 /PRNewswire/ -- Cohera Medical, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that its lead product, TissuGlu® Surgical Adhesive, is a finalist for the 2012 Medical Design Excellence Awards in the General Hospital Devices and Therapeutic Products category.

The Medical Design Excellence Awards is the medical device industry's premier design awards competition and is the only awards program that exclusively recognizes contributions and advances in the design of medical products. The program recognizes the achievements of medical product manufacturers and the many people behind the scenes – engineers, scientists, designers, and clinicians – who are responsible for the groundbreaking innovations that are changing the face of healthcare. Entries are evaluated on the basis of their design and engineering features.

TissuGlu is an internal surgical adhesive for large flap surgeries, such as abdominoplasties, that helps reduce fluid accumulation and the need for postsurgical drains. Its unique chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may provide the patient with a quicker return to normal activity.

"We are very pleased that TissuGlu Surgical Adhesive has been recognized as one of this year's most innovative medical products in the industry by the MDEA judges," said Patrick Daly, President & CEO, Cohera Medical. "This award is a reflection of Cohera's excellence in designing cutting-edge technology that will help surgeons improve the overall care of their patients."

Currently, most patients who undergo abdominoplasty procedures and other flap procedures require the insertion of drains to remove fluids that accumulate under the skin at the surgical site. In some cases, drainage is inadequate and the excess fluid accumulation (seroma) requires additional procedures for removal. TissuGlu adheres the tissue flap created during the procedure to the underlying tissue, helping to reduce the fluid that can accumulate in the space and ultimately reducing the time to drain removal. The use of TissuGlu may shorten the length of time that drains need to be in place, leading to a more comfortable recovery and a quicker return to normal activity for patients.

This year's MDEA finalists will be announced in the April Issue of Medical Device and Diagnostic Industry (www.mddionline.com) magazine.  The winners will be announced in May at a special presentation ceremony held in conjunction with the Medical Design & Manufacturing (MD&M) East Event (www.MDMEast.com), May 22-24, 2012, at the Pennsylvania Convention Center in Philadelphia.

About Cohera Medical

Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that eliminates or reduces fluid accumulation and the need for post surgical drains.  TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU).  Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for sale or marketing by the Food and Drug Administration (FDA) in the U.S. or in any other market.  For more information, visit www.coheramed.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cohera Medical Receives IDE Approval to Begin Pivotal Clinical Trial for TissuGlu® Surgical Adhesive in the U.S.
2. Cohera Medical Commercializes TissuGlu® Surgical Adhesive in Germany
3. Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive
4. Frost & Sullivan Recognizes Cohera Medical, Inc.® for Developing TissuGlu®, Its Pioneering Surgical Adhesive That Is Strong, Easy-To-Use, Biocompatible and Resorbable
5. 12 Month TRAM Data Collated Using TIGR® Matrix Surgical Mesh in a Randomized Controlled Study Presented at MAPACS 2012
6. Stryker Launches Next Generation Heavy Duty Surgical Power Tools
7. Checkpoint Surgical Receives CE Mark
8. Electrosurgical Devices Market to Grow at a CAGR of 5% Globally From 2011-2018
9. Texas Court of Appeals Holds That Specialized Surgical Instruments are Exempt Orthopedic Devices
10. Novus Scientific & Surgical Momentum Partner for Continuous Quality Improvement Program (CQI)
11. Largest Neurosurgical Center in Russia Acquires Elektas Leksell Gamma Knife Perfexion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):